

The European Communities (Coronavirus Vaccine) (Immunity from Civil Liability) (Guernsey) Ordinance, 2020

THE STATES POLICY & RESOURCES COMMITTEE, in exercise of the powers conferred on the States by sections 1 and 4 of the European Communities (Implementation) (Bailiwick of Guernsey) Law, 1994^a and all other powers enabling them in that behalf, and on the Committee by Article 66A(1) of the Reform (Guernsey) Law, 1948^b, hereby order:-

Application of this Ordinance.

1. (1) This Ordinance applies where –
 - (a) the UK licensing authority has authorised a medicinal product on a temporary basis (whether with or without conditions) under regulation 174 of the Human Medicines Regulations 2012^c,
 - (b) the Committee has designated the medicinal product to be used for vaccination or immunisation against the

^a Ordres en Conseil Vol. XXXV (1), p. 65; as amended by Order in Council No. I of 2019.

^b Ordres en Conseil Vol. XIII, p. 288; as amended by Order in Council No. XVII of 2015; there are other amendments not material to this Ordinance.

^c UK S.I. 2012 No. 1916.

coronavirus under regulations made under section 15(2) and (3) of the Prescription Only Medicines (Human) (Bailiwick of Guernsey) Ordinance, 2009^d, and

- (c) a medicinal product falling within the description or class of the designated vaccine has been sold, supplied or administered by a person specified in section 3 in accordance with –
 - (i) a Patient Group Direction approved or consented to by the Committee, or
 - (ii) a protocol.

(2) In subsection (1)(a), "**UK licensing authority**" means the licensing authority within the meaning given by regulation 6(2) of the Human Medicines Regulations 2012.

Exclusion of civil liability

2. (1) Where this Ordinance applies, none of the persons specified in section 3 are to be subject to any civil liability for any loss or damage arising out of or in connection with any person receiving the relevant medicinal product administered in accordance with the Patient Group Direction or (as the case may be) protocol.

(2) Subsection (1) is subject to section 4.

^d Ordinance No. XXV of 2009; as amended by No. XXV of 2010; No. IX of 2016; No. XXXIV of 2020.

Persons excluded from civil liability.

3. Sections 1(c) and 2(1) refer to the following persons –
- (a) any person responsible for the sale, supply, procurement for sale or supply, procurement for manufacture or assembly, or otherwise placing on the market in Guernsey, of the relevant medicinal product, in the course of a business carried on by the person,
 - (b) any officer, servant, employee or agent of a person described in paragraph (a),
 - (c) any person specified in Part II of Schedule 2 to the Prescription Only Medicines (Human) (Bailiwick of Guernsey) Ordinance, 2009,
 - (d) any dentist, nurse independent prescriber, pharmacist independent prescriber or supplementary prescriber, within the meaning given to each of these terms by section 20(1) of the Prescription Only Medicines (Human) (Bailiwick of Guernsey) Ordinance, 2009,
 - (e) any medical practitioner registered under the Regulation of Health Professions (Medical Practitioners) (Guernsey and Alderney) Ordinance, 2015^e, and

^e Ordinance No. XXII of 2015; as amended by No. L of 2015 and No. IX of 2016.

- (f) where section 1(1)(c)(ii) applies, any person (not being a person mentioned in any of paragraphs (a) to (e)) who sold, supplied or (as the case may be) administered the relevant medicinal product in accordance with the protocol mentioned in section 1(1)(c)(ii).

Time of sale, supply or administration.

4. The exclusion of liability in section 2(1) applies only in respect of a relevant medicinal product sold, supplied or (as the case may be) administered –

- (a) after this Ordinance comes into force, and
- (b) if the designated vaccine is given a United Kingdom marketing authorisation or a European Union marketing authorisation within the meaning given by regulations 12 and 13(1), respectively, of the Medicines (Human) (Exemptions and Recognition of Marketing Authorisations) (Bailiwick of Guernsey) Regulations, 2009^f, before it is given either marketing authorisation concerned.

Interpretation.

5. In this Ordinance, unless the context requires otherwise –

"the Committee" means the Committee for Health & Social Care,

^f G.S.I. No. 63 of 2009.

"**the coronavirus**" has the meaning given by section 15(3) of the Prescription Only Medicines (Human (Bailiwick of Guernsey) Ordinance, 2009,

"**designated vaccine**" means the medicinal product designated in accordance with section 1(1)(b),

"**medicinal product**" has the meaning given by section 133 of the Medicines (Human and Veterinary) (Bailiwick of Guernsey) Law, 2008[§],

"**Patient Group Direction**" has the meaning given by section 15(4) of the Prescription Only Medicines (Human (Bailiwick of Guernsey) Ordinance, 2009,

"**protocol**" means any protocol for the sale, supply or administration of the designated vaccine approved under or for the purposes of section 15A of the Prescription Only Medicines (Human (Bailiwick of Guernsey) Ordinance, 2009, and

"**relevant medicinal product**" means the medicinal product sold, supplied or (as the case may be) administered in accordance with section 1(1)(c).

Extent.

6. This Ordinance has effect in Guernsey.

[§] Order in Council No. V of 2009; as amended by Ordinance No. XXIV of 2009; No. XLI of 2013; No. IX of 2016.

Citation.

7. This Ordinance may be cited as the European Communities (Coronavirus Vaccine) (Immunity from Civil Liability) (Guernsey) Ordinance, 2020.

Commencement.

8. This Ordinance shall come into force on the 15th December, 2020.